Regeneron Pharmaceuticals, Inc. (BVL:REGN)

Market Cap	209.76B
Revenue (ttm)	50.32B
Net Income (ttm)	15.78B
Shares Out	n/a
EPS (ttm)	140.44
PE Ratio	13.29
Forward PE	14.17
Dividend	9.64 (1.62%)
Ex-Dividend Date	Aug 18, 2025

Volume	n/a
Average Volume	2
Open	n/a
Previous Close	596.50
Day's Range	n/a
52-Week Range	565.20 - 1,058.63
Beta	n/a
RSI	38.10
Earnings Date	Nov 3, 2025

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq...

• Industry: Pharmaceutical Preparations
• Founded: 1988
• Employees: 15,106
• Stock Exchange: Lima Stock Exchange
• Ticker Symbol: REGN

Financial Performance

In 2024, Regeneron Pharmaceuticals's revenue was $14.20 billion, an increase of 8.27% compared to the previous year's $13.12 billion. Earnings were $4.41 billion, an increase of 11.61%.

Financial numbers in USD